Can Industry Learn to Share? - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Can Industry Learn to Share?
The regulators are doing it. But industry's fear of sharing information may leave them behind.

Pharmaceutical Technology
Volume 33, Issue 7, pp. 14

Angie Drakulich
The US Food and Drug Administration has been sharing inspection information with its regulatory counterparts in the European Union and Australia since last July as part of a pilot program under the federal Interagency Working Group on Import Safety. Now, industry is forming an international pharmaceutical supply chain consortium known as Rx–360 to, among other objectives, create a shared program for auditing suppliers.

The growing consortium is very similar to a model for third-party shared audits of active pharmaceutical ingredient suppliers run by the European Chemical Industry Council's Active Pharmaceutical Ingredients Committee.

But is industry really willing to join in the sharing game? We're all taught to share from an early age, but somewhere along the line, we get caught up in competition and slowly decrease our eagerness to confide in peers. Competition is important—it is the foundation of our economy—and in the field of science, intellectual property rights and company proprietary information require individuals to remain private about the details of their work. But perhaps this hiding of information has gone too far. There must be a way industry can learn to share without giving up all its trade secrets.

Consider this: To meet all the new requirements for securing the supply chain, industry would have to conduct 800,000 audits per year, said Rx-360's Martin Van Trieste at the June consortium launch meeting. Unless pharma firms are planning to go on a massive hiring spree—perhaps alleviating the US unemployment rate along the way—to conduct these audits, it may be time for industry to start sharing.

Angie Drakulich is the managing editor of Pharmaceutical Technology.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here